Oceania Healthcare (OCA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
2 Aug, 2026Opening remarks and agenda
Meeting convened in person and online, with safety and participation protocols outlined.
Quorum confirmed and meeting formally opened; agenda included annual report, director elections, auditor remuneration, and shareholder proposals.
Board and executive committee updates
Board succession included the re-election of Elizabeth Coutts, election of Sarah Ottrey, and retirement of Sally Evans after eight years.
Board renewal highlighted as deliberate and skills-led, with staggered director rotation.
Board committees streamlined to four, with risk oversight merged into Audit & Risk and sustainability elevated to the full Board.
Executive team restructured for clearer portfolios and productivity, with one leader at every site.
Sally Evans recognized for her eight years of service and leadership in care and sustainability.
Financial performance review
Record pro forma underlying EBITDA up 20.2% to NZD 97.7 million; sales volumes up 16% to 603 settlements.
Net debt reduced by $121 million to $507 million; gearing at 30%, with NZD 200 million headroom.
Free cash flow from operations improved by 64% to $(15.0)m, with a goal to turn positive in FY 2027.
Cost savings of $13.2 million delivered in FY26, annualizing to $20 million in FY27, targeting $30 million by FY 2027.
Care earnings per occupied bed increased 40%, with occupancy at 95.5%.
Latest events from Oceania Healthcare
- Secured bond offer funds growth and debt reduction, with record FY26 results and strong sustainability.OCA
Investor presentation - Record sales, EBITDA growth, and debt reduction position for positive cash flow in FY27.OCA
H2 2026 - Underlying EBITDA up 19%, gearing at 34.8%, and strong sales drive improved results.OCA
H1 2026 - Disciplined execution and service innovation drive sustainable growth and returns to FY31.OCA
Investor Day 2025 Presentation - Underlying EBITDA rose 4.1% as sales volumes and operational efficiency both improved.OCA
Investor Presentation - Asset and sales growth, no FY25 dividend, and focus on efficiency and sustainability.OCA
AGM 2025 - EBITDA up, cash flow strong, but net profit down; sales and debt reduction remain key priorities.OCA
H1 2025 - Strong financial growth, reinvestment, and innovation highlighted at the AGM.OCA
AGM 2024 - EBITDA up 4.1%, sales volumes up 9.2%, and cost savings of up to $20m targeted.OCA
H2 2025